Duke spinout Element could generate as much as $30m from the sale, which will enable UCB to boost its research capabilities.
Element Genomics, a US-based genomics technology spinout from Duke University, was acquired by biopharmaceutical developer UCB today in a deal sized at up to $30m depending on upfront and short-run performance milestones.
Founded in 2015, Element Genomics is working on a genomics-based platform that would enable researchers to identify new drug targets more easily by acting as a high-throughput screening system for gene regulatory elements, the DNA component which influences other genes in the human genome.
The technology could enhance…
